NasdaqGS - Delayed Quote USD

Mesoblast Limited (MESO)

6.24 +0.09 (+1.46%)
At close: 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MESO

Recent News: MESO

View More
Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%

Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
Simply Wall St. 18 hours ago
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up

Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Zacks 30 days ago
After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
Benzinga last month
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
GlobeNewswire last month
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
GlobeNewswire last month
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
GlobeNewswire last month
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript

Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
Insider Monkey last month
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag

Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. last month
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
GlobeNewswire last month
Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Financial Results and Corporate Update Webcast
GlobeNewswire last month
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
GlobeNewswire 2 months ago
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
GlobeNewswire 2 months ago
View More

Related Tickers

RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9900
+0.34%
 
CADL Candel Therapeutics, Inc.
6.39
-0.62%
 
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.5300
+12.77%
 
IMMP Immutep Limited
2.6500
+1.92%
 
TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
 
ASLN ASLAN Pharmaceuticals Limited
0.4153
-7.30%
 
IBIO iBio, Inc.
1.7600
+2.33%
 
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
 
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
 
PCSA Processa Pharmaceuticals, Inc.
2.1500
-11.52%